Hepatic sialic acid synthesis modulates glucose homeostasis in both liver and skeletal muscle

Molecular Metabolism - Tập 78 - Trang 101812 - 2023
Jun Peng1, Liming Yu1, Linzhang Huang1, Vivian A. Paschoal2, Haiyan Chu1, Camila O. de Souza2, Joseph V. Varre3, Da Young Oh2, Jennifer J. Kohler4, Xue Xiao5, Lin Xu5, William L. Holland3, Philip W. Shaul1, Chieko Mineo1,6
1Center for Pulmonary and Vascular Biology, Dept. of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390, USA
2Dept. of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390, USA
3Dept. of Nutrition & Integrative Physiology, University of Utah College of Health, 250 1850 E, Salt Lake City, UT, 84112, USA
4Dept. of Biochemistry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390, USA
5Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390, USA
6Dept. of Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390, USA

Tài liệu tham khảo

Varki, 2008, Sialic acids in human health and disease, Trends Mol Med, 14, 351, 10.1016/j.molmed.2008.06.002

Traving, 1998, Structure, function and metabolism of sialic acids, Cell Mol Life Sci, 54, 1330, 10.1007/s000180050258

Varki, 2012, Multifarious roles of sialic acids in immunity, Ann N Y Acad Sci, 1253, 16, 10.1111/j.1749-6632.2012.06517.x

Schnaar, 2022, Glycosphingolipids, 129

Hinderlich, 1997, A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat liver. Purification and characterization of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase, J Biol Chem, 272, 24313, 10.1074/jbc.272.39.24313

Stasche, 1997, A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat liver. Molecular cloning and functional expression of UDP-N-acetyl-glucosamine 2-epimerase/N-acetylmannosamine kinase, J Biol Chem, 272, 24319, 10.1074/jbc.272.39.24319

Pham, 2017, Effects of altered sialic acid biosynthesis on N-linked glycan branching and cell surface interactions, J Biol Chem, 292, 9637, 10.1074/jbc.M116.764597

Schwarzkopf, 2002, Sialylation is essential for early development in mice, Proc Natl Acad Sci U S A, 99, 5267, 10.1073/pnas.072066199

Rudman, 2019, Altered N-glycosylation profiles as potential biomarkers and drug targets in diabetes, FEBS Lett, 593, 1598, 10.1002/1873-3468.13495

Dotz, 2019, N-glycome signatures in human plasma: associations with physiology and major diseases, FEBS Lett, 593, 2966, 10.1002/1873-3468.13598

Klaver, 2019, Selective inhibition of N-linked glycosylation impairs receptor tyrosine kinase processing, Dis Model Mech, 12

Johswich, 2014, N-glycan remodeling on glucagon receptor is an effector of nutrient sensing by the hexosamine biosynthesis pathway, J Biol Chem, 289, 15927, 10.1074/jbc.M114.563734

Dridi, 2013, Positive regulation of insulin signaling by neuraminidase 1, Diabetes, 62, 2338, 10.2337/db12-1825

Samuel, 2016, The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux, J Clin Invest, 126, 12, 10.1172/JCI77812

Ramnanan, 2011, Physiologic action of glucagon on liver glucose metabolism, Diabetes Obes Metab, 13, 118, 10.1111/j.1463-1326.2011.01454.x

Geng, 2020, The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic, Nat Rev Endocrinol, 16, 654, 10.1038/s41574-020-0386-0

Kehlenbrink, 2012, Elevated NEFA levels impair glucose effectiveness by increasing net hepatic glycogenolysis, Diabetologia, 55, 3021, 10.1007/s00125-012-2662-6

Carrillo, 2018, GNE myopathy: etiology, diagnosis, and therapeutic challenges, Neurotherapeutics, 15, 900, 10.1007/s13311-018-0671-y

Ran, 2013, Genome engineering using the CRISPR-Cas9 system, Nat Protoc, 8, 2281, 10.1038/nprot.2013.143

Titchenell, 2015, Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo, Nat Commun, 6, 7078, 10.1038/ncomms8078

Byun, 2020, Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase, Nat Commun, 11, 807, 10.1038/s41467-020-14384-z

Li, 2016, Hematopoietic-derived galectin-3 causes cellular and systemic insulin resistance, Cell, 167, 973, 10.1016/j.cell.2016.10.025

Paschoal, 2020, Positive reinforcing mechanisms between GPR120 and PPARγ modulate insulin sensitivity, Cell Metab, 31, 1173, 10.1016/j.cmet.2020.04.020

Virkamäki, 1997, Incorporation of [3-3H]glucose and 2-[1-14C]deoxyglucose into glycogen in heart and skeletal muscle in vivo: implications for the quantitation of tissue glucose uptake, Diabetes, 46, 1106, 10.2337/diab.46.7.1106

Mauvais-Jarvis, 2000, A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes, Diabetes, 49, 2126, 10.2337/diabetes.49.12.2126

Zisman, 2000, Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance, Nat Med, 6, 924, 10.1038/78693

Ying, 2019, Expansion of islet-resident macrophages leads to inflammation affecting beta cell proliferation and function in obesity, Cell Metab, 29, 457, 10.1016/j.cmet.2018.12.003

Tanigaki, 2018, Hyposialylated IgG activates endothelial IgG receptor FcγRIIB to promote obesity-induced insulin resistance, J Clin Invest, 128, 309, 10.1172/JCI89333

Charni-Natan, 2020, Protocol for primary mouse hepatocyte isolation, STAR Protoc, 1, 10.1016/j.xpro.2020.100086

Miller, 2013, Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP, Nature, 494, 256, 10.1038/nature11808

Siu, 2013, Structure of the human glucagon class B G-protein-coupled receptor, Nature, 499, 444, 10.1038/nature12393

Weston, 2015, Modulation of glucagon receptor Pharmacology by receptor activity-modifying protein-2 (RAMP2), J Biol Chem, 290, 23009, 10.1074/jbc.M114.624601

Valdez-Sinon, 2020, Protocol for immuno-enrichment of FLAG-tagged protein complexes, STAR Protoc, 1, 10.1016/j.xpro.2020.100083

Huang, 2019, SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis, Nature, 569, 565, 10.1038/s41586-019-1140-4

Elleman, 2000, Mutational analysis of the N-linked glycosylation sites of the human insulin receptor, Biochem J, 347, 771, 10.1042/bj3470771

Hwang, 2000, Alternative glycosylation of the insulin receptor prevents oligomerization and acquisition of insulin-dependent tyrosine kinase activity, Biochim Biophys Acta, 1499, 74, 10.1016/S0167-4889(00)00109-9

Sparrow, 2007, The location and characterisation of the O-linked glycans of the human insulin receptor, Proteins, 66, 261, 10.1002/prot.21261

Sparrow, 2008, N-linked glycans of the human insulin receptor and their distribution over the crystal structure, Proteins, 71, 426, 10.1002/prot.21768

Liu, 2022, Insulin induces insulin receptor degradation in the liver through EphB4, Nat Metab, 4, 1202, 10.1038/s42255-022-00634-5

Janah, 2019, Glucagon receptor signaling and glucagon resistance, Int J Mol Sci, 20, 10.3390/ijms20133314

Holst, 1994, Proglucagon processing in porcine and human pancreas, J Biol Chem, 269, 18827, 10.1016/S0021-9258(17)32241-X

Gelling, 2003, Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice, Proc Natl Acad Sci U S A, 100, 1438, 10.1073/pnas.0237106100

Lee, 2011, Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice, Diabetes, 60, 391, 10.2337/db10-0426

Okamoto, 2017, Glucagon receptor inhibition normalizes blood glucose in severe insulin-resistant mice, Proc Natl Acad Sci U S A, 114, 2753, 10.1073/pnas.1621069114

Habegger, 2010, The metabolic actions of glucagon revisited, Nat Rev Endocrinol, 6, 689, 10.1038/nrendo.2010.187

Seamon, 1981, Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells, Proc Natl Acad Sci U S A, 78, 3363, 10.1073/pnas.78.6.3363

Leavens, 2011, Insulin signaling to hepatic lipid metabolism in health and disease, Crit Rev Biochem Mol Biol, 46, 200, 10.3109/10409238.2011.562481

Galsgaard, 2019, Glucagon receptor signaling and lipid metabolism, Front Physiol, 10, 413, 10.3389/fphys.2019.00413

Ling, 2018, FoxO1 is required for most of the metabolic and hormonal perturbations produced by hepatic insulin receptor deletion in male mice, Endocrinology, 159, 1253, 10.1210/en.2017-00870

Stohr, 2021, FoxO1 suppresses Fgf21 during hepatic insulin resistance to impair peripheral glucose utilization and acute cold tolerance, Cell Rep, 34, 10.1016/j.celrep.2021.108893

Sostre-Colon, 2022, Acute deletion of the FOXO1-dependent hepatokine FGF21 does not alter basal glucose homeostasis or lipolysis in mice, Endocrinology, 163, 10.1210/endocr/bqac035

Reily, 2019, Glycosylation in health and disease, Nat Rev Nephrol, 15, 346, 10.1038/s41581-019-0129-4

Fujita-Yamaguchi, 1985, Removal of sialic acids from the purified insulin receptor results in enhanced insulin-binding and kinase activities, Biochem Biophys Res Commun, 129, 739, 10.1016/0006-291X(85)91954-0

Salhanick, 1988, Role of sialic acid in insulin action and the insulin resistance of diabetes mellitus, Am J Physiol, 255, E173

Fougerat, 2018, Neuraminidase 1 activates insulin receptor and reverses insulin resistance in obese mice, Mol Metab, 12, 76, 10.1016/j.molmet.2018.03.017

Uehara, 2023, Insulin regulation of hepatic lipid homeostasis, Compr Physiol, 13, 4785, 10.1002/cphy.c220015

Markan, 2014, Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding, Diabetes, 63, 4057, 10.2337/db14-0595

Camporez, 2013, Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice, Endocrinology, 154, 3099, 10.1210/en.2013-1191

Jaiswal, 2019, The role of skeletal muscle Akt in the regulation of muscle mass and glucose homeostasis, Mol Metab, 28, 1, 10.1016/j.molmet.2019.08.001

Sasako, 2022, Deletion of skeletal muscle Akt1/2 causes osteosarcopenia and reduces lifespan in mice, Nat Commun, 13, 5655, 10.1038/s41467-022-33008-2

Lai, 2012, A novel PKB/Akt inhibitor, MK-2206, effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle, Biochem J, 447, 137, 10.1042/BJ20120772

Small, 2019, Reduced insulin action in muscle of high fat diet rats over the diurnal cycle is not associated with defective insulin signaling, Mol Metab, 25, 107, 10.1016/j.molmet.2019.04.006

Marette, 2014, Skeletal muscle glucose metabolism and inflammation in the development of the metabolic syndrome, Rev Endocr Metab Disord, 15, 299, 10.1007/s11154-014-9296-6

Dotz, 2018, Plasma protein N-glycan signatures of type 2 diabetes, Biochim Biophys Acta Gen Subj, 1862, 2613, 10.1016/j.bbagen.2018.08.005

Adua, 2019, High throughput profiling of whole plasma N-glycans in type II diabetes mellitus patients and healthy individuals: a perspective from a Ghanaian population, Arch Biochem Biophys, 661, 10, 10.1016/j.abb.2018.10.015

Keser, 2017, Increased plasma N-glycome complexity is associated with higher risk of type 2 diabetes, Diabetologia, 60, 2352, 10.1007/s00125-017-4426-9

Bansal, 2021, Association of serum sialic acid concentration with diabetic complications and cardiovascular risk factors in an Indian population, Arch Med Sci Atheroscler Dis, 6, e14, 10.5114/amsad.2021.105142

Ekin, 2003, Comparative study of total protein, and total and lipid-associated serum sialic acid levels in patients with type 2 diabetes mellitus, J Clin Lab Anal, 17, 124, 10.1002/jcla.10078

Englyst, 2006, Percentage of body fat and plasma glucose predict plasma sialic acid concentration in type 2 diabetes mellitus, Metabolism, 55, 1165, 10.1016/j.metabol.2006.04.014

Gavella, 2003, Serum sialic acid in subjects with impaired glucose tolerance and in newly diagnosed type 2 diabetic patients, Acta Diabetol, 40, 95, 10.1007/s005920300012

Ibrahim, 2016, Modulation of sialic acid levels among some organs during insulin resistance or hyperglycemic states, Mol Cell Biochem, 411, 235, 10.1007/s11010-015-2585-x

Khalili, 2014, Sialic acid and incidence of hospitalization for diabetes and its complications during 40-years of follow-up in a large cohort: the Varmland survey, Prim Care Diabetes, 8, 352, 10.1016/j.pcd.2014.06.002

Scheen, 2017, Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes, Expert Opin Investig Drugs, 26, 1373, 10.1080/13543784.2017.1395020

Guzman, 2017, Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes, Diabetes Obes Metab, 19, 1521, 10.1111/dom.12958

Thông tin
Thông tin xuất bản

Molecular Metabolism

Tập 78

101812

Thông tin tác giả